Female Reproductive & Breast

Pelvic pain: chronic pelvic pain workup

Clinical Overview and When to Suspect Chronic Pelvic Pain

— Prevalence ~15% of US women aged 18–50; accounts for ~10% of outpatient gynecology visits, 20% of laparoscopies, and 12% of hysterectomies.

— Direct + indirect annual US costs exceed $2 billion; major driver of opioid prescribing in reproductive-age women.

— Symptoms >6 months, prior negative acute workup, multiple prior providers, escalating analgesic use, sleep/work/sexual dysfunction.

— Pain disproportionate to exam, or pain that has "spread" beyond original site (suggests central sensitization).

— Gynecologic: endometriosis, adenomyosis, leiomyoma, pelvic adhesions, pelvic congestion syndrome, chronic PID, ovarian remnant.

— Urologic: interstitial cystitis/bladder pain syndrome (IC/BPS), recurrent UTI, urolithiasis.

— GI: IBS, inflammatory bowel disease, chronic constipation, diverticular disease.

— Musculoskeletal/neurologic: myofascial pelvic floor dysfunction, pudendal neuralgia, abdominal wall trigger points, ilioinguinal/iliohypogastric entrapment.

— Psychosocial: depression, anxiety, PTSD, history of sexual or physical abuse (present in 40–50%).

Definition: Noncyclic or cyclic pelvic pain ≥6 months in duration, localized to the anatomic pelvis, anterior abdominal wall at or below the umbilicus, lumbosacral back, or buttocks, severe enough to cause functional disability or prompt medical care.

Epidemiology:

When to suspect a chronic (vs acute) etiology:

Core conceptual model — chronic pelvic pain is multifactorial:

Step 3 management: Approach chronic pelvic pain as a biopsychosocial syndrome, not a single-organ problem. The board-correct workflow is structured history → focused multisystem exam → tiered noninvasive testing → empiric trial of targeted therapy → laparoscopy only when noninvasive workup is nondiagnostic and surgical findings would alter management.

Board pearl: Up to one-third of diagnostic laparoscopies for CPP are negative, and a normal laparoscopy does not exclude endometriosis, adhesions causing pain, or central sensitization — counsel patients before surgery.

Presentation Patterns and Key History

— Onset/timing: Cyclic with menses → endometriosis, adenomyosis, primary dysmenorrhea. Noncyclic constant → adhesions, IC/BPS, myofascial. Mid-cycle → mittelschmerz, ovulatory.

— Quality: Cramping (uterine origin), burning/stabbing (neuropathic, pudendal), pressure/bloating (GI, congestion), sharp positional (musculoskeletal).

— Radiation: Back/thigh (endometriosis, pudendal), groin (hernia, ureter), perineum (pelvic floor, pudendal).

— Aggravators: Intercourse (deep dyspareunia → endometriosis, adhesions; entry dyspareunia → vulvodynia, vaginismus, atrophy), bladder filling (IC/BPS), defecation (endometriosis on rectosigmoid, IBS), prolonged sitting (pudendal neuralgia, coccygodynia).

— Gyn: Menstrual pattern, dysmenorrhea severity, dyspareunia, infertility, abnormal bleeding, prior STIs/PID, prior pelvic surgery.

— Uro: Urgency, frequency, nocturia, dysuria without infection, hematuria, suprapubic pain relieved by voiding.

— GI: Rome IV criteria for IBS (recurrent abdominal pain ≥1 day/week ×3 months, related to defecation or stool change), constipation, hematochezia, weight loss.

— MSK/neuro: Falls, lifting injuries, posture, exercise pattern, numbness/paresthesias in saddle distribution.

— PHQ-9, GAD-7, validated trauma screen.

— Ask explicitly: "Have you ever experienced unwanted sexual contact?" — 40–50% of CPP patients report a history of abuse.

— Substance use, opioid history, sleep, social support, relationship impact.

Pain characterization (OPQRST applied to pelvis):

Targeted system-by-system review:

Psychosocial screen (mandatory, not optional):

Red flags requiring urgent workup: postmenopausal bleeding, unintentional weight loss, hematuria, hematochezia, palpable mass, fever, new-onset pain >50, family history of gynecologic/GI malignancy.

Board pearl: A pain diary correlating symptoms to menses, voiding, bowel movements, intercourse, and stress for 2 menstrual cycles is the single highest-yield outpatient tool — order it at the first visit.

Key distinction: Cyclic pain peaking just before/with menses suggests endometriosis/adenomyosis; noncyclic pain worsened by bladder filling and relieved by voiding suggests IC/BPS.

Physical Exam Findings and Systematic Assessment

— Observe gait, posture, ability to sit comfortably.

— Abdominal inspection for surgical scars (adhesions), bulges (hernia), striae.

— Carnett sign: Palpate tender spot, then have patient tense abdominal wall by lifting head/legs. Increased pain = abdominal wall origin (trigger point, nerve entrapment); decreased pain = visceral origin. High yield on boards.

— Palpate along iliohypogastric, ilioinguinal, and genitofemoral nerve distributions for entrapment (often near Pfannenstiel scar).

— Inspect vulva for lesions, atrophy, dermatoses; cotton-swab test for provoked vestibulodynia (point tenderness at vestibular gland openings).

— Insert one finger to systematically palpate:

– Levator ani (puborectalis, pubococcygeus, iliococcygeus) — tenderness or trigger points = myofascial pelvic floor pain.

– Obturator internus, piriformis — lateral wall tenderness.

– Pudendal nerve at ischial spine — reproduction of pain = pudendal neuralgia.

– Bladder base, urethra — anterior tenderness suggests IC/BPS.

– Uterosacral ligaments, cul-de-sac — nodularity/tenderness = endometriosis.

— Cervical motion tenderness, adnexal masses, uterine size/mobility/tenderness on bimanual.

General and abdominal exam:

Single-digit pelvic exam (do this FIRST, before bimanual):

Rectovaginal exam: Essential for posterior cul-de-sac endometriosis, rectovaginal septum nodules, rectal masses.

Musculoskeletal: SI joint provocation (FABER), hip ROM, sacrococcygeal palpation, posture/lumbar exam.

Key distinction: Speculum exam first in women with possible vulvodynia/vaginismus is a pitfall — start with gentle external inspection and cotton-swab testing; a forced speculum can re-traumatize and ends the encounter.

Step 3 management: Document a pain map at the index visit — labeled diagram of tender sites (abdominal wall, levators, bladder, adnexa, cul-de-sac). This drives differential weighting and lets you track response to therapy objectively at follow-up.

Board pearl: Reproducing the patient's exact pain on focused palpation of the levator ani localizes ≥50% of "gynecologic" CPP to the pelvic floor, not the uterus or ovaries.

Diagnostic Workup — Initial Labs and Imaging

— Urinalysis + urine culture (rule out infection, microscopic hematuria).

— Urine pregnancy test (β-hCG) — mandatory in reproductive-age women before imaging/medications.

— CBC (anemia from menorrhagia, leukocytosis if infectious).

— STI testing: NAAT for gonorrhea and chlamydia (chronic PID, Fitz-Hugh–Curtis sequelae).

— Vaginal wet mount/pH if discharge.

— TSH, fasting glucose if systemic symptoms.

— Fecal calprotectin or CRP if IBD suspected; celiac serology if bloating + diarrhea.

— CA-125 only if pelvic mass on exam/imaging — not a screening test, elevated in endometriosis, fibroids, PID, pregnancy, menses, ascites.

— Urine cytology if hematuria + >35 years or smoking history.

— Best initial test for structural gynecologic pathology.

— Detects: endometriomas (ground-glass cysts), adenomyosis (heterogeneous myometrium, asymmetric wall thickening, subendometrial cysts, "venetian-blind" shadowing), leiomyomas, hydrosalpinx, ovarian cysts, IUD position.

— Sensitive for deep infiltrating endometriosis when performed by experienced sonographer with bowel prep ("expert TVUS").

— Second-line when TVUS equivocal, suspected deep infiltrating endometriosis (rectovaginal, bladder, ureteral), Müllerian anomaly, or surgical planning.

— Best modality for adenomyosis confirmation (junctional zone >12 mm).

Targeted, not shotgun, testing. The yield of broad lab panels in CPP is low; order based on history and exam.

First-line labs (most patients):

Add based on clinical clues:

First-line imaging — transvaginal ultrasound (TVUS):

MRI pelvis (with and without contrast):

What NOT to order routinely: CT abdomen/pelvis (poor soft-tissue resolution, radiation), diagnostic laparoscopy as a first step, broad autoimmune panels.

Step 3 management: A reproductive-age woman with cyclic pelvic pain, deep dyspareunia, and normal exam should get β-hCG → TVUS → STI NAAT before any specialty referral or surgery — that sequence answers the board question nearly every time.

Board pearl: A normal TVUS does NOT exclude endometriosis — superficial peritoneal disease is invisible on imaging. Empiric medical therapy is appropriate before laparoscopy.

Diagnostic Workup — Advanced and Confirmatory Studies

— Reserved for: persistent pain despite empiric medical therapy, suspected endometriosis where surgical confirmation/treatment will change management, suspected adhesive disease, infertility evaluation.

— Gold standard for endometriosis diagnosis (visual ± biopsy), though empiric treatment is now first-line per ACOG/ASRM.

— Findings: powder-burn lesions, clear/red vesicles, endometriomas, adhesions, cul-de-sac obliteration.

— Counsel: ~30% of laparoscopies for CPP are negative; negative does not exclude pain-generating pathology.

— For suspected IC/BPS with hematuria, refractory symptoms, or to exclude bladder malignancy/stones.

— May show glomerulations or Hunner lesions (10–15%, more severe phenotype).

— Diagnosis of IC/BPS is clinical; cystoscopy is not required for initial diagnosis (AUA guidelines).

— Trigger-point injection of abdominal wall with lidocaine — sustained relief confirms myofascial source.

— Pudendal nerve block (transvaginal or image-guided) — relief supports pudendal neuralgia (Nantes criteria).

— Superior hypogastric plexus block — both diagnostic and therapeutic for visceral pelvic pain.

Diagnostic laparoscopy:

Cystoscopy with hydrodistention:

Urodynamics: Only if mixed incontinence or neurogenic bladder suspected.

Colonoscopy: If GI red flags (bleeding, weight loss, anemia, age ≥45 unscreened), alarm features, or suspected IBD/malignancy.

Pelvic floor assessment by trained PT: Quantifies tone, trigger points, prolapse, coordination — often diagnostic and therapeutic.

Nerve blocks as diagnostic tools:

MR neurography: For suspected pudendal or sacral plexus neuropathy when blocks ambiguous.

Pelvic venography or MR/CT venogram: For pelvic congestion syndrome — dilated parametrial/ovarian veins (>6 mm), reflux on Valsalva, in multiparous woman with positional pain worse standing.

Key distinction: Endometriosis = laparoscopy gold standard but empirically treated; adenomyosis = MRI gold standard, definitive only on hysterectomy specimen; IC/BPS = clinical diagnosis, cystoscopy supportive.

Board pearl: Sustained pain relief after a diagnostic local anesthetic block is both confirmatory and prognostic — it identifies patients who will benefit from targeted neuromodulation or surgical decompression rather than systemic therapy.

Risk Stratification and First-Line Management Logic

— Identify 1–3 most likely contributors from history/exam (e.g., endometriosis + pelvic floor myofascial pain + IBS).

— Treat all contributing domains simultaneously; single-organ approaches usually fail.

— Realistic: 30–50% pain reduction, improved function, restored sleep/sex/work — not "cure."

— Use validated measures: NRS, Pelvic Pain Impact Questionnaire, EHP-30 for endometriosis.

— Tier 1 (all patients): Education, validation, pain diary, sleep hygiene, exercise, dietary modification (low-FODMAP for IBS overlap, bladder-irritant elimination for IC/BPS), pelvic floor PT referral if levator tenderness, CBT or pain psychology referral.

— Tier 2 (mechanism-targeted pharmacotherapy): NSAIDs scheduled (not PRN) for cyclic pain; combined hormonal contraceptive or progestin for suspected endometriosis/adenomyosis; tricyclic antidepressant (amitriptyline) or SNRI for neuropathic/centralized pain; antispasmodics or low-dose TCA for IBS overlap.

— Tier 3: GnRH agonist/antagonist with add-back, neuromodulators (gabapentin, pregabalin), trigger-point injections, nerve blocks.

— Tier 4: Laparoscopic excision of endometriosis, adhesiolysis, presacral neurectomy, hysterectomy (definitive only after counseling — does not guarantee pain relief, especially if central sensitization).

— Chronic opioids (no evidence of long-term benefit; high harm; CDC 2022 guideline).

— Repeated laparoscopies in the same patient without new findings.

— Hysterectomy as first-line for nonspecific CPP.

Step 3 framework — match therapy to the dominant pain generator(s):

Goal-setting at first visit:

Tiered treatment ladder:

When to involve multidisciplinary pelvic pain clinic: ≥2 organ systems involved, failure of 3 months tier-2 therapy, opioid use, significant psychosocial comorbidity.

Avoid:

Step 3 management: The board-favored answer for a new CPP patient with cyclic pain, dyspareunia, and tender pelvic floor on exam is start NSAIDs + combined OCP + pelvic floor PT and reassess in 3 months — before ordering laparoscopy.

Board pearl: Centralized pain features (widespread pain, fatigue, poor sleep, high catastrophizing on PCS) predict poor response to surgery — these patients need pain-psychology and neuromodulator-based plans, not the OR.

Pharmacotherapy — First-Line Drug Regimens

— Naproxen 500 mg BID or ibuprofen 600–800 mg TID, started 1–2 days before menses, scheduled ×3–5 days.

— Mechanism: prostaglandin suppression.

— Caution: GI ulcer, renal impairment, cardiovascular risk; add PPI if high GI risk.

— Combined hormonal contraceptive (CHC) continuously (skip placebo) — first-line, suppresses ovulation and menstruation, reduces dysmenorrhea and endometriosis-related pain.

— Progestin-only options: norethindrone acetate 5 mg daily, levonorgestrel 52 mg IUD (excellent for adenomyosis, dysmenorrhea), DMPA, dienogest 2 mg (where available).

— GnRH antagonists (elagolix, relugolix combo) — oral, rapid onset, dose-dependent hypoestrogenic effects; relugolix combo includes add-back estradiol/norethindrone, allowing longer use (up to 24 months).

— GnRH agonists (leuprolide) with add-back therapy (norethindrone 5 mg ± low-dose estrogen) — limits BMD loss, vasomotor symptoms; max 6–12 months without add-back.

— Amitriptyline 10–25 mg qhs, titrate to 50–75 mg — first-line for IC/BPS, vulvodynia, centralized CPP; helps sleep.

— Duloxetine 30→60 mg daily — SNRI, evidence in chronic musculoskeletal and centralized pain, useful with comorbid depression.

— Gabapentin 300 mg qhs → titrate to 1800–3600 mg/day divided; pregabalin 75 mg BID → 150–300 mg BID.

— Pentosan polysulfate 100 mg TID (caution: pigmentary maculopathy — annual ophtho exam).

— Intravesical DMSO, heparin, or lidocaine instillations.

NSAIDs (first-line for cyclic/dysmenorrheal component):

Hormonal suppression (suspected endometriosis/adenomyosis):

Neuropathic/centralized pain:

IC/BPS-specific:

IBS overlap: Antispasmodics (hyoscyamine, dicyclomine), peppermint oil, low-dose TCA, linaclotide/lubiprostone for IBS-C, rifaximin/eluxadoline for IBS-D.

Avoid: Chronic opioids, benzodiazepines as primary pain therapy.

Board pearl: First-line empiric regimen for suspected endometriosis in a woman not seeking pregnancy = continuous CHC + scheduled NSAIDs; if inadequate at 3 months → progestin or GnRH antagonist; laparoscopy reserved for refractory disease or fertility evaluation.

Key distinction: GnRH agonists cause initial flare (downregulation) and need add-back; GnRH antagonists (elagolix, relugolix) suppress immediately without flare — preferred when rapid effect needed.

Procedures and Invasive Management

— Indicated for: pain refractory to ≥3 months medical therapy, endometriomas >3–4 cm, infertility evaluation, suspected deep infiltrating disease.

— Excision preferred over ablation for deep lesions; recurrence ~20–40% over 5 years.

— Postoperative hormonal suppression (CHC, progestin, LNG-IUD) reduces recurrence.

— Modest pain benefit only for dense adhesions; randomized data show limited benefit for filmy adhesions. Counsel cautiously.

— Endometrial ablation — for dysmenorrhea + heavy bleeding in women not desiring fertility; ineffective for adenomyosis pain.

— Uterine artery embolization (UAE) — fibroids and adenomyosis; preserves uterus, not fertility-preserving in standard counseling.

— Hysterectomy ± BSO — definitive for uterine sources (adenomyosis, fibroids, refractory endometriosis). 75–95% pain improvement when uterus is the dominant source; 20–40% have persistent pain if pelvic floor or centralized component unaddressed. Preserve ovaries when possible in premenopausal women.

— Trigger-point injections (abdominal wall, levator) with lidocaine ± steroid.

— Pudendal nerve block (image-guided); repeated blocks or pulsed radiofrequency for pudendal neuralgia.

— Superior hypogastric plexus block / neurolysis for visceral pelvic pain (often oncologic, sometimes CPP).

— Sacral neuromodulation (InterStim) — IC/BPS, refractory pelvic pain with urinary symptoms.

— Botulinum toxin injection into levator ani for refractory pelvic floor myofascial pain.

— Presacral neurectomy — modest benefit for midline dysmenorrhea, risks constipation/urinary dysfunction.

— LUNA (laparoscopic uterosacral nerve ablation) — not recommended; no benefit over sham.

Laparoscopic excision/ablation of endometriosis:

Adhesiolysis:

Uterine-targeted procedures:

Neuromodulatory procedures:

Procedures largely abandoned or limited:

Pelvic congestion syndrome: Ovarian/internal iliac vein embolization is first-line invasive therapy.

CCS pearl: When the simulated case shows refractory CPP and you've ordered TVUS, MRI, empiric CHC, PT, and a neuromodulator — the next correct order is referral to a multidisciplinary pelvic pain center or gynecology subspecialist, not another laparoscopy.

Board pearl: Counsel every patient considering hysterectomy for CPP that pain persists in up to 40% if non-uterine generators (pelvic floor, bladder, bowel, central sensitization) are present — pre-op multidisciplinary evaluation is standard of care.

Special Populations — Older Adults and Renal/Hepatic Impairment

— Always exclude malignancy first: ovarian, endometrial, cervical, vulvar, colorectal, bladder cancers.

— Postmenopausal bleeding + pelvic pain → endometrial biopsy + TVUS (endometrial stripe >4 mm requires sampling).

— Adnexal mass + ascites + elevated CA-125 → gyn-onc referral.

— Genitourinary syndrome of menopause (GSM): atrophic vulvovaginitis, dyspareunia, urinary symptoms; first-line vaginal estrogen (cream, ring, tablet) — safe even in many breast cancer survivors after oncology discussion.

— Pelvic organ prolapse: pressure, heaviness, "ball" sensation; pessary or surgical repair.

— Pelvic floor dysfunction, recurrent UTI, urolithiasis, diverticulitis.

— Vulvar lichen sclerosus — pruritic, "cigarette paper" skin, fissures; high-potency topical steroid (clobetasol); increased SCC risk → annual exam.

— Avoid NSAIDs — accelerate CKD progression, AKI risk; use acetaminophen, topical agents.

— Gabapentin/pregabalin: dose-reduce based on CrCl (gabapentin 300 mg daily if CrCl 30–59; lower for severe CKD).

— Duloxetine: avoid if CrCl <30.

— Tramadol, codeine: reduced clearance; avoid or reduce dose.

— Acetaminophen: ≤2 g/day in cirrhosis.

— NSAIDs: avoid (variceal bleeding, hepatorenal syndrome).

— TCAs, duloxetine: hepatically metabolized — duloxetine contraindicated in chronic liver disease with cirrhosis.

— CHCs: contraindicated in active liver disease, hepatic adenoma, severe cirrhosis.

— Beers criteria: avoid TCAs (anticholinergic), benzodiazepines, long-term NSAIDs, muscle relaxants in older adults.

— Prefer SNRI duloxetine or topical lidocaine over systemic neuropathic agents.

Postmenopausal women with pelvic pain — fundamentally different differential:

Common benign causes in older women:

Renal impairment (CKD stage 3–5):

Hepatic impairment:

Polypharmacy in older adults:

Step 3 management: New-onset pelvic pain in a postmenopausal woman is malignancy until proven otherwise — TVUS + endometrial biopsy (if bleeding) + age-appropriate cancer screening review is the index workup, not empiric hormonal therapy.

Board pearl: Vaginal estrogen for GSM produces minimal systemic absorption and is the highest-yield, most underused intervention for older women presenting with dyspareunia and recurrent UTI.

Special Populations — Pregnancy, Adolescents, and Other Subgroups

— Acute pelvic pain in pregnancy ≠ CPP; always rule out ectopic, miscarriage, abruption, ovarian torsion, appendicitis, pyelonephritis before attributing to chronic causes.

— Many CPP medications are contraindicated: NSAIDs (avoid after 20 weeks — oligohydramnios, ductal closure; avoid third trimester), hormonal therapy, GnRH analogs, gabapentinoids (limited data), duloxetine (use caution).

— Acetaminophen is preferred analgesic.

— Pelvic girdle pain and round ligament pain are common — managed with PT, support belts, positioning.

— Symphysis pubis dysfunction — PT, acetaminophen.

— Primary dysmenorrhea is most common cause; first-line NSAIDs + CHC.

— Suspect endometriosis if dysmenorrhea refractory to NSAIDs + CHC ×3 months — adolescents often have atypical (red/clear) lesions; early diagnosis matters.

— Müllerian anomalies (obstructed hemivagina, noncommunicating uterine horn) cause cyclic pain with normal menses — MRI is diagnostic.

— Confidentiality: HIPAA + state minor consent laws for contraception, STI testing.

— Endometriosis and adhesions overlap CPP and infertility; coordinate with REI.

— Hormonal suppression delays conception — balance against pain control.

— Surgical excision of endometriomas improves pain but may reduce ovarian reserve (AMH drop) — counsel before cystectomy.

— Higher prevalence of CPP, vulvodynia, vaginismus, IC/BPS.

— Trauma-informed care: explicit consent for each step, option to defer exam, mental health co-management, female chaperone.

— Inclusive language; transgender men on testosterone may have atrophic vaginitis, pelvic pain — vaginal estrogen compatible.

Pregnancy:

Adolescents:

Infertility patients:

Survivors of sexual trauma:

LGBTQ+ patients:

Board pearl: A 14-year-old with cyclic pelvic pain and normal menarche but a pelvic mass on TVUS likely has an obstructed Müllerian anomaly (e.g., OHVIRA: obstructed hemivagina with ipsilateral renal agenesis) — get MRI and renal ultrasound.

Step 3 management: Adolescent with dysmenorrhea unresponsive to NSAIDs + 3 months continuous CHC → empiric trial of progestin or GnRH antagonist + referral for diagnostic laparoscopy if symptoms persist; do not delay diagnosis years into adulthood.

Complications and Adverse Outcomes

— Central sensitization: Persistent peripheral nociceptive input causes CNS amplification; pain spreads, becomes constant, refractory to peripheral therapies. Predicts poor surgical outcome.

— Functional disability: Work absence, job loss, disability claims; ~25% of CPP patients miss work monthly.

— Sexual dysfunction: Dyspareunia → avoidance → vaginismus → relationship strain.

— Sleep disturbance, fatigue, fibromyalgia overlap.

— Depression in 30–50%, anxiety in 20–30%, PTSD especially in trauma survivors.

— Suicidality risk elevated — screen at every visit (PHQ-9 item 9).

— Opioid use disorder risk; long-term opioids worsen pain (opioid-induced hyperalgesia) and rarely improve function.

— Cannabis, alcohol self-medication.

— Multiple surgeries: Each laparoscopy increases adhesion burden; "adhesion cycle" worsens future pain and surgical risk.

— Post-hysterectomy persistent pain in 20–40%; ovarian remnant syndrome if incomplete oophorectomy.

— Surgical injury to ureter, bowel, bladder, nerves (especially ilioinguinal, genitofemoral).

— GnRH-induced bone loss if used >6 months without add-back.

— NSAID GI bleeding, AKI; TCA anticholinergic side effects, QT prolongation; CHC VTE risk.

— Endometriosis-associated infertility; adhesions impair tubal function.

— Some treatments (DMPA, GnRH analogs) reversibly delay return to fertility.

— Diagnostic delay for endometriosis averages 7–10 years — repeated dismissals, normalization of severe dysmenorrhea, gender bias.

— Polypharmacy, fragmented care across gyn/uro/GI/pain specialists.

Pain-related complications:

Mental health:

Substance use:

Iatrogenic complications:

Fertility implications:

Healthcare system harms:

Board pearl: Persistent pain after technically successful hysterectomy in a CPP patient should prompt evaluation for pelvic floor myofascial pain, bladder pain syndrome, ovarian remnant, and central sensitization — not another exploratory surgery.

Step 3 management: Document opioid risk assessment (PDMP check, opioid risk tool), naloxone co-prescription, and clear taper plan if a CPP patient inherits chronic opioids from a prior provider; do not refill indefinitely.

When to Escalate Care — Consults, Referrals, and Inpatient Triage

— Acute change in chronic pain pattern with peritoneal signs, hypotension, fever — rule out ectopic, torsion, ruptured cyst, PID/TOA, appendicitis, bowel perforation.

— Suspected tubo-ovarian abscess — IV antibiotics (cefotetan or ceftriaxone + doxycycline + metronidazole), drainage if >7 cm or not responding in 48–72 h.

— Severe dehydration, intractable vomiting (e.g., obstructive Müllerian anomaly).

— Active suicidal ideation with plan.

— Pelvic mass with concerning features (solid, septated, ascites, elevated CA-125, age >50) → gyn-oncology within 2 weeks per NCCN.

— Postmenopausal bleeding → endometrial biopsy within 1–2 weeks.

— Suspected deep infiltrating endometriosis with bowel/bladder involvement → endometriosis specialist.

— Gynecology: Surgical evaluation for refractory endometriosis, fibroids, adenomyosis.

— Urology/urogynecology: Refractory IC/BPS, hematuria, prolapse, fistula.

— Gastroenterology: Refractory IBS, IBD, alarm features.

— Pelvic floor PT: Levator tenderness, dyspareunia, prolapse, postpartum pain — high-yield, often underutilized.

— Pain medicine: Multimodal pharmacology, nerve blocks, neuromodulation.

— Pain psychology / CBT therapist: Centralized pain, catastrophizing, trauma history.

— Psychiatry: Comorbid major depression, PTSD, substance use.

— Reproductive endocrinology: Concurrent infertility.

Emergency department / inpatient triage indications:

Urgent (same-week) referral:

Subspecialty referrals (outpatient):

Multidisciplinary pelvic pain clinic when ≥2 systems involved, >6 months of failed therapy, or opioid use.

CCS pearl: In a simulated CCS case of CPP with worsening symptoms, the high-value clock orders are: pelvic floor PT consult, pain psychology referral, and continuation of empiric hormonal therapy — racking up consults to gyn-onc or pain medicine without these foundational referrals loses points.

Step 3 management: A 32-year-old with 8 months of pelvic pain, levator tenderness, dyspareunia, and bladder symptoms should be referred concurrently to pelvic floor PT + urogynecology/urology + pain psychology — parallel, not sequential, referrals shorten time to functional recovery.

Key Differentials — Same-Category (Gynecologic) Causes

— Cyclic pain peaking with menses, deep dyspareunia, dyschezia, infertility; may have uterosacral nodularity.

— TVUS may show endometriomas; superficial disease invisible; laparoscopy gold standard.

— Treat empirically with CHC/progestin/GnRH antagonist before surgery.

— Heavy, painful menses + globular tender uterus in parous woman >35.

— TVUS/MRI: heterogeneous myometrium, junctional zone >12 mm.

— LNG-IUD, CHC, GnRH antagonist; hysterectomy definitive.

— Pressure, bulk symptoms, heavy bleeding, sometimes pain (degenerating fibroid, torsed pedunculated).

— TVUS diagnostic; tranexamic acid, CHC, LNG-IUD, GnRH antagonist with add-back, UAE, myomectomy, hysterectomy.

— Post-surgical, post-PID; cyclic or noncyclic.

— Imaging insensitive; laparoscopic diagnosis. Adhesiolysis modest benefit.

— Prior PID history, perihepatic adhesions causing RUQ pain.

— STI screening, treat acute episodes, prevent reinfection.

— Multiparous, dull aching pain worse with prolonged standing/end of day, postcoital ache, vulvar/thigh varicosities.

— Doppler/MR venography; ovarian vein embolization.

— Cyclic pain after BSO — residual ovarian tissue.

— Pelvic mass on imaging; elevated estradiol, suppressed FSH if functional remnant; surgical excision.

— Entry dyspareunia, point tenderness on cotton-swab test, normal exam otherwise.

— Topical lidocaine, TCA, pelvic floor PT, CBT.

Endometriosis:

Adenomyosis:

Leiomyomas (fibroids):

Pelvic adhesive disease:

Chronic PID / Fitz-Hugh–Curtis:

Pelvic congestion syndrome:

Ovarian remnant syndrome:

Vulvodynia / provoked vestibulodynia:

Müllerian anomalies (adolescents): Obstructed hemivagina, noncommunicating horn — cyclic pain, MRI diagnostic.

Key distinction: Endometriosis pain is cyclic and progressive with deep dyspareunia and uterosacral nodularity; adenomyosis pain is cyclic with heavy bleeding and a tender, boggy, globular uterus; fibroids cause bulk/bleeding more than pain unless degenerating.

Board pearl: The combination of dysmenorrhea + dyspareunia + dyschezia + infertility ("the four Ds") in a reproductive-age woman is endometriosis on the boards until proven otherwise — start empiric CHC, do not wait for laparoscopic confirmation.

Key Differentials — Other-Category (Non-Gynecologic) Causes

— Interstitial cystitis/bladder pain syndrome (IC/BPS): Suprapubic pain with bladder filling, relief with voiding, urgency/frequency without infection, negative urine cultures. Clinical diagnosis. Treat with bladder-irritant elimination, amitriptyline, pentosan polysulfate, intravesical therapy, pelvic floor PT.

— Recurrent UTI, urolithiasis, bladder cancer (especially in smokers with hematuria).

— IBS (Rome IV): Recurrent abdominal pain ≥1 day/week ×3 months, associated with defecation or stool change. Overlaps CPP in 30–50%. Fiber, antispasmodics, low-FODMAP, TCAs, peppermint oil.

— IBD, diverticular disease, chronic constipation, colorectal cancer (age-appropriate screening).

— Celiac disease — bloating, diarrhea, anemia.

— Pelvic floor myofascial pain: Levator tenderness, trigger points, dyspareunia, dyschezia, urinary urgency. Pelvic floor PT first-line.

— Abdominal wall trigger points / nerve entrapment: Positive Carnett sign; ilioinguinal, iliohypogastric, genitofemoral nerves (often post-Pfannenstiel). Trigger-point injection diagnostic/therapeutic.

— Pudendal neuralgia (Nantes criteria): Pain in pudendal distribution, worse sitting (relieved on toilet seat), no sensory loss, relief with pudendal block. PT, gabapentin, blocks, decompression surgery.

— Coccygodynia, SI joint dysfunction, hip pathology (labral tear, FAI), lumbar radiculopathy.

— Major depression, anxiety, PTSD, somatic symptom disorder.

— Fibromyalgia overlap — widespread pain, fatigue, cognitive symptoms.

Urologic:

Gastrointestinal:

Musculoskeletal/neurologic:

Psychiatric / centralized:

Endocrine/metabolic: Porphyria (rare); hypothyroidism worsens constipation/pain.

Hernia: Inguinal, femoral, obturator; sports hernia in athletes.

Key distinction: IC/BPS pain worsens with bladder filling and improves with voiding; endometriosis pain is cyclic with menses; myofascial pain is reproduced by palpation of the levator ani; IBS pain is related to defecation and stool changes. Asking these four questions sorts most CPP differentials at the bedside.

Board pearl: Up to 80% of patients with CPP have ≥2 contributing diagnoses (e.g., endometriosis + IBS + pelvic floor dysfunction). The exam answer that treats only one is usually wrong; the answer involving multimodal, multidisciplinary care is usually right.

Secondary Prevention, Discharge Medications, and Long-Term Plan

— Continue CHC, progestin, or LNG-IUD until pregnancy desired or menopause.

— Reassess every 6–12 months for efficacy, side effects, contraindications (new VTE risk, hypertension, migraine with aura → switch CHC to progestin-only).

— GnRH antagonist + add-back can be continued up to 24 months (relugolix combo); monitor BMD if approaching limits.

— Continued pelvic floor PT home exercise program; periodic "tune-ups" with PT for flares.

— Avoid Kegels if hypertonic pelvic floor — counterintuitive but critical.

— Bladder-irritant diet (avoid citrus, caffeine, alcohol, spicy, artificial sweeteners).

— Maintenance amitriptyline or hydroxyzine; periodic intravesical therapy.

— Sustained low-FODMAP or fiber regimen, antispasmodics PRN, ongoing TCA/SNRI if effective.

— Ongoing CBT, mindfulness-based stress reduction, acceptance and commitment therapy.

— Antidepressant continuation; do not abruptly stop SNRIs/TCAs.

— Regular aerobic exercise (improves pain, mood, sleep), yoga, sleep hygiene.

— Smoking cessation (worsens IC/BPS, bladder cancer risk).

— Weight optimization if indicated.

— Cervical cancer screening per USPSTF (Pap ± HPV ages 21–65).

— Mammography per guidelines.

— Colorectal screening starting at 45.

— Bone density if on GnRH analog >6–12 months or postmenopausal.

— Annual vulvar exam in patients with lichen sclerosus (SCC surveillance).

— Vaccinations: HPV (up to age 45 shared decision), flu, COVID, Tdap.

— If on opioids, document indication, function goals, PDMP, urine drug screen, naloxone co-prescription, taper plan.

Long-term hormonal suppression (endometriosis/adenomyosis):

Maintenance of pelvic floor health:

IC/BPS maintenance:

IBS overlap:

Mental health and pain psychology:

Lifestyle:

Routine preventive care (do not forget):

Opioid stewardship:

Step 3 management: Every CPP patient leaving your office with a new prescription needs a 3-month follow-up appointment scheduled at checkout, validated pain/function reassessment tool, and a written plan listing therapies across medical, physical, and psychological domains.

Board pearl: Continuous (skip-placebo) hormonal contraception is the single most cost-effective long-term intervention for endometriosis-associated CPP in a patient not seeking pregnancy.

Follow-Up, Monitoring Parameters, and Counseling

— 2–4 weeks after starting new pharmacotherapy: tolerability, side effects, adherence.

— 3 months: Reassess pain (NRS), function (work, sleep, sex), validated tools (EHP-30, ICPI for IC, IBS-SSS, PHQ-9, GAD-7). Adjust regimen if <30% improvement.

— 6 months: Comprehensive reassessment; decide on escalation, continuation, or de-escalation.

— Annually: Long-term maintenance, BMD if applicable, contraception/fertility goals review.

— CHC: Blood pressure annually; VTE/migraine review at each visit.

— GnRH agonist >6 months / GnRH antagonist long-term: BMD (DXA) baseline and yearly; ensure add-back; calcium/vitamin D.

— TCA/SNRI: Suicidality screen first 1–4 weeks, anticholinergic burden in older adults; ECG if QT concerns (high-dose TCA).

— Gabapentinoids: Sedation, edema, mood; do not abruptly stop.

— Pentosan polysulfate: Annual ophthalmologic exam (pigmentary maculopathy).

— NSAIDs: Renal function (Cr), BP, GI symptoms every 6–12 months.

— LNG-IUD: String check, expulsion symptoms; replace every 7–8 years (varies by product).

— Validation: "Your pain is real" — many CPP patients have been dismissed; this alone has therapeutic value.

— Education: Pain neuroscience education (PNE) reduces catastrophizing and improves outcomes.

— Realistic expectations: Goal is improved function, not zero pain.

— Self-management tools: Pain diary, heat/cold, paced exercise, mindfulness apps.

— Sexual health: Lubricants, position changes, communication, sex therapy if needed.

— Fertility: Discuss timing of family planning relative to hormonal therapy.

— NRS pain score, days of missed work, quality of life, sexual function, sleep, opioid use, ED/hospital visits.

Follow-up cadence:

Monitoring by therapy:

Counseling pillars:

Outcome metrics that matter (track over time):

Step 3 management: At every CPP follow-up, document four domains: pain score, function, mental health screen, and treatment adherence/side effects — this is the board-favored structured visit and the medicolegal standard.

Board pearl: A 30% reduction in pain or function score is a clinically meaningful response; do not abandon a therapy as ineffective before a 3-month trial at adequate dose.

Ethical, Legal, and Patient Safety Considerations

— Women with CPP face documented dismissal and diagnostic delay (endometriosis avg 7–10 years). Recognize and counteract gender, racial, and weight-based bias. Black women receive less analgesia and longer diagnostic delays — explicitly mitigate.

— Before laparoscopy or hysterectomy for CPP, explicitly counsel that 20–40% of patients have persistent pain post-procedure; document this in chart.

— Consent for hysterectomy must include alternatives, fertility implications, ovary preservation decisions, surgical risks (ureter/bowel/bladder injury).

— In adolescents, balance minor consent laws, parental involvement, and confidentiality for contraception/STI/mental health.

— 40–50% of CPP patients report sexual or physical abuse history. Ask permission for each step of pelvic exam, offer a chaperone, allow patient to stop at any time, never force exam.

— Document trauma history sensitively; coordinate mental health support.

— Suspected intimate partner violence: most US states permit but do not mandate; mandatory in injuries from weapons. Domestic violence resources, safety planning.

— Suspected child abuse in adolescent patients — mandatory reporting in all 50 states.

— Elder abuse reporting in older patients.

— Check prescription drug monitoring program before prescribing controlled substances.

— Co-prescribe naloxone if MME >50/day or concurrent benzodiazepines.

— Document risk assessment, treatment agreement, urine drug screening.

— Hand-offs between gyn, uro, GI, pain medicine create medication errors. Maintain a single primary "captain" (often PCP or pelvic pain clinic lead) who reconciles medications and coordinates.

— Post-hysterectomy, ensure patient knows whether ovaries were preserved (impacts future contraception, HRT decisions).

— Pelvic pain involves sensitive sexual/reproductive content — HIPAA-protected; release records only with explicit consent; secure messaging only.

— Document functional limitations objectively for FMLA, ADA, or short-term disability paperwork.

Validation and diagnostic bias:

Informed consent:

Trauma-informed care:

Mandatory reporting:

Opioid stewardship and PDMP:

Transition-of-care safety:

Privacy:

Disability and work accommodations:

Step 3 management: A 16-year-old presents alone requesting evaluation for chronic dysmenorrhea and asks that her parents not be informed she is sexually active and using contraception — provide confidential STI testing and contraception per state minor consent law, encourage but do not require parental involvement, document confidentiality discussion.

Board pearl: Refusing to perform a pelvic exam at the patient's request is always acceptable — defer the exam, build trust, offer alternatives (history, imaging, self-collected swabs); a forced exam is assault and ends therapeutic relationship.

High-Yield Associations and Rapid-Fire Clinical Facts

— Cyclic dysmenorrhea, deep dyspareunia, dyschezia, infertility, uterosacral nodularity, "powder-burn" lesions, chocolate cysts (endometriomas).

— Empiric first-line: continuous CHC + NSAIDs.

— Diagnostic gold standard: laparoscopy with histology.

— Recurrence after surgery without suppression: ~50% at 5 years.

Endometriosis classics:

Adenomyosis: Globular tender uterus, heavy painful menses in parous woman >35, junctional zone >12 mm on MRI, definitive dx on hysterectomy specimen.

Fibroids: Most common pelvic tumor; bulk symptoms > pain; submucosal type causes most bleeding; degenerating fibroid in pregnancy causes acute pain.

IC/BPS: Pain with bladder filling, relief with voiding, urgency/frequency, sterile urine. Hunner lesions in ~10%. First-line: bladder-irritant diet + amitriptyline + pelvic floor PT.

Pelvic congestion syndrome: Multiparous, worse standing, vulvar varices, ovarian vein reflux — ovarian vein embolization.

Pudendal neuralgia (Nantes criteria): Pain in pudendal distribution, worse sitting, relief on toilet seat, no sensory loss, positive pudendal block.

Carnett sign: Pain worsens with tensed abdominal wall → wall origin (trigger point/nerve entrapment), not visceral.

Vulvodynia: Cotton-swab test reproduces vestibular pain; normal exam otherwise; topical lidocaine, TCA, pelvic floor PT.

OHVIRA syndrome: Obstructed hemivagina + ipsilateral renal agenesis — cyclic pain post-menarche with normal menses.

CA-125: Not a screening test; elevated in endometriosis, fibroids, PID, menses, pregnancy, ascites, ovarian cancer. Useful for postmenopausal adnexal mass risk stratification.

GnRH agonist vs antagonist: Agonist causes flare, needs add-back; antagonist (elagolix, relugolix) acts immediately.

LNG-IUD: Best progestin delivery for adenomyosis and dysmenorrhea.

Pentosan polysulfate: Annual eye exam (maculopathy).

Endometriosis diagnostic delay: 7–10 years average — drives advocacy and early empiric treatment.

Post-hysterectomy CPP: Persistent pain in 20–40% — investigate pelvic floor, bladder, bowel, central sensitization, ovarian remnant.

Centralized pain features: Widespread pain + fatigue + poor sleep + catastrophizing → poor surgical outcome → favor non-surgical multimodal therapy.

Board pearl: Whenever the stem mentions dysmenorrhea + deep dyspareunia + infertility, the answer involves endometriosis and the next step is usually empiric CHC, not laparoscopy.

Key distinction: Cyclic + heavy bleeding + globular uterus = adenomyosis; cyclic + uterosacral nodularity + infertility = endometriosis.

Board Question Stem Patterns

— 28-year-old G0 with 3 years of progressive dysmenorrhea, deep dyspareunia, dyschezia during menses, primary infertility ×1 year. Exam: tender uterosacral nodularity, retroverted uterus. TVUS normal.

— Answer: Empiric continuous combined OCP + scheduled NSAIDs; refer for fertility evaluation. Not immediate laparoscopy. Not hysterectomy.

— 42-year-old G3P3 with heavy painful menses, bulky tender boggy globular uterus 12-week size, TVUS shows asymmetric myometrium with subendometrial cysts.

— Answer: LNG-IUD (if not desiring fertility) or GnRH antagonist; MRI to confirm if surgery considered; hysterectomy definitive.

— 35-year-old with 8 months of suprapubic pain worsening with bladder filling and relieved by voiding, urinary frequency 15×/day, negative urine cultures ×3.

— Answer: Bladder-irritant elimination diet + amitriptyline + pelvic floor PT; cystoscopy not required for diagnosis.

— Postpartum patient with dyspareunia, constant pelvic pressure, exam shows tender levator ani.

— Answer: Pelvic floor physical therapy.

— Pain localized to Pfannenstiel scar, positive Carnett sign.

— Answer: Trigger-point injection with lidocaine; consider nerve entrapment (ilioinguinal/iliohypogastric).

— Burning perineal pain worse sitting, relieved on toilet seat; no sensory loss.

— Answer: Pelvic floor PT + gabapentin; diagnostic/therapeutic pudendal nerve block.

— Multiparous woman with dull pelvic ache worsening through the day, postcoital ache, vulvar varices.

— Answer: Doppler/MR venography; ovarian vein embolization.

— 62-year-old with new pelvic pain, bloating, early satiety, ascites, CA-125 elevated.

— Answer: Urgent gyn-oncology referral; suspect ovarian cancer.

— 14-year-old with normal menarche but cyclic pain and pelvic mass, unilateral renal agenesis on history.

— Answer: MRI pelvis; OHVIRA syndrome; surgical correction.

— Persistent pain after hysterectomy for "endometriosis"; exam shows tender levators.

— Answer: Pelvic floor PT, pain psychology, multimodal therapy — not repeat surgery.

Stem 1 — Classic endometriosis:

Stem 2 — Adenomyosis:

Stem 3 — IC/BPS:

Stem 4 — Pelvic floor myofascial pain:

Stem 5 — Abdominal wall trigger point:

Stem 6 — Pudendal neuralgia:

Stem 7 — Pelvic congestion:

Stem 8 — Postmenopausal new pelvic pain:

Stem 9 — Adolescent obstructed Müllerian anomaly:

Stem 10 — Refractory CPP post-hysterectomy:

Board pearl: Stems describing multiple organ systems with negative imaging point toward multimodal therapy and pelvic floor PT as the right answer — beware the trap of jumping to laparoscopy or hysterectomy.

Step 3 management: When the stem ends with "What is the next best step?" for a CPP patient who has had only NSAIDs, the answer is almost always add hormonal suppression and refer to pelvic floor PT before any surgical option.

One-Line Recap

Chronic pelvic pain is a multifactorial biopsychosocial syndrome that demands a structured history, focused multisystem exam (including levator and Carnett testing), tiered noninvasive workup (β-hCG, UA, STI NAAT, TVUS ± MRI), and simultaneous multimodal therapy across gynecologic, urologic, GI, musculoskeletal, and psychological domains — with laparoscopy reserved for refractory or fertility-driven cases and hysterectomy as a last resort after counseling that 20–40% have persistent pain.

— Workup sequence: β-hCG → UA/culture → STI NAAT → TVUS → MRI if equivocal or deep infiltrating endometriosis suspected → laparoscopy only when noninvasive workup is exhausted and surgical findings will change management.

— Empiric first-line for suspected endometriosis (no fertility desired): continuous combined OCP + scheduled NSAIDs ×3 months; escalate to progestin, LNG-IUD, or GnRH antagonist if inadequate.

— Always examine the pelvic floor: Levator tenderness identifies a treatable myofascial pain generator in >50% of CPP — refer to pelvic floor PT, the most underused high-yield intervention.

— Treat the whole patient: Address mental health, trauma history, sleep, sexual function, and central sensitization concurrently; opioids are not first-line and usually worsen long-term outcomes.

High-yield recap bullets:

Final Step 3 management pearl: The exam-correct disposition for nearly every new CPP patient is a 3-month multimodal trial (hormonal suppression + NSAIDs + pelvic floor PT + pain psychology) with structured follow-up using validated pain and function scores, escalating only after that foundation is in place — not surgery, not opioids, not more imaging.

Board pearl: When in doubt on a CPP question, choose the answer that treats multiple contributors at once, validates the patient, and includes pelvic floor physical therapy or behavioral health — single-organ, single-modality answers are nearly always the distractors.